RxDoctor Payments Data

Todd Firmatura, MD

Family Medicine · White Hall, ARNPI 1326545401

Payments from drug & device makers

$1,437in general payments, 2019–2025

Across 78 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$412
  • Novo Nordisk$212
  • Lilly USA, LLC$175
  • AstraZeneca$155
  • Pfizer$111
  • Merck$78
  • plus $293 from 10 others

What the payments were for

  • Food & beverage$1,437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,437 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$283,296
Medicare patients
404
Services billed
7,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$56,181
MounjaroTirzepatide30$44,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$40,718
EliquisApixaban35$36,454
JardianceEmpagliflozin31$26,072
JanuviaSitagliptin Phosphate24$21,197
RybelsusSemaglutide11$19,101
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$17,917
EntrestoSacubitril/Valsartan21$14,098
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,659
Spiriva HandihalerTiotropium Bromide11$6,396
FarxigaDapagliflozin Propanediol15$6,327
Repatha SureclickEvolocumab12$6,240
VascepaIcosapent Ethyl11$4,387
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$212$75,28275 claims
Lilly USA, LLCMounjaro, Olanzapine$175$45,51743 claims
GSKTrelegy Ellipta$16$40,71850 claims
PfizerEliquis$111$36,45435 claims
AstraZenecaBreztri Aerosphere, Farxiga$155$24,24435 claims
MerckJanuvia$78$21,19724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in White Hall

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →